Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 4regorafenib 2pembrolizumab 2Drug Therapy 2Cisplatin 2vocimagene amiretrorepvec 1ulixertinib 1spartalizumab 1motexafin gadolinium 1erythromycin propionate-N-acetylcysteinate 1epacadostat 1durvalumab 1depatuxizumab mafodotin 1cobimetinib 1cc-486 1aflibercept 1Thalidomide 1Tamoxifen 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1NEO212 1Molecular Diagnostic Techniques 1Ipilimumab 1Injections 1Immunotherapy 1IFL protocol 1Gemcitabine 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × depatuxizumab mafodotin × Head & Neck × Clear all
NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡